ALX Oncology Holdings (NASDAQ:
ALXO) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.46) by 3.7 percent. This is a 16.32 percent increase over losses of $(0.57) per share from the same period last year.